Active Pharmaceutical Ingredients
PRODUCT | CAS NO | THERAPEUTIC CATEGORY | PHARMACOPOEIA | STATUS |
---|---|---|---|---|
Fexofenadine Hydrochloride | 153439-40-8 | Antihistaminic | IP/USP/EP/JP | Developed |
Citicoline Sodium | 33818-15-4 | Psychostimulant | IP/USP | Developed |
Phenylephrine Hydrochloride | 61-76-7 | Decongestant | IP/USP/EP | Developed |
Dexketoprofen Trometamol | 156604-79-4 | Anti-Inflammatory | In-House | Developed |
Ursodeoxycholic Acid | 128-13-2 | Cholelithiasis Agent | IP/USP/EP | Developed |
Dapagliflozin Propanediol | 960404-48-2 | Antidiabetic | In-House | Developed |
Dapagliflozin Amorphous | 461432-26-8 | Antidiabetic | In-House | Developed |
Alpha Lipoic Acid | 1077-28-7 | Antioxidant | IP/USP/EP | Developed |
Tolvaptan | 150683-30-0 | Diuretic | Under development | |
Ezetimibe | 163222-33-1 | Antihyperlipidemic | Under development | |
Bempedoic Acid | 738606-46-7 | Lipid Lowering Agent | Under development | |
Obeticholic Acid | 459789-99-2 | Gastrointestinal Agent | In Pipeline | |
Montelukast Sodium | 151767-02-1 | Anti-Asthmatic | In Pipeline | |
Bilastine | 202189-78-4 | Antihistaminic | In Pipeline | |
Tranexamic Acid | 1197-18-8 | Antifibrinolytic | In Pipeline |
Intermediates
PRODUCT | CAS NO | END API | INTERMEDIATE CODE | STATUS |
---|---|---|---|---|
N-(2 -Cyanobiphenyl-4-ylmethyl)-L-valine Methyl Ester Hydrochloride | 482577-59-3 | Valsartan | Developed | |
2,3,4,6-Tetrakis-O-trimethylsilyl-D-gluconolactone | 32384-65-9 | Dapagliflozin/Empagliflozin | Developed | |
4-Bromo-1-chloro-2-(4-ethoxybenzyl)benzene | 461432-23-5 | Dapagliflozin | Developed | |
Methyl 2-(4-(4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butanoyl)phenyl)-2-methylpropanoate | 154477-55-1 | Fexofenadine | Developed | |
Phenylephrine Base | 59-42-7 | Phenylephrine Hydrochloride | Developed | |
L-proline benzyl ester hydrochloride | 16652-71-4 | Lisinopril | Developed | |
7-Ethyltryptophol | 41340-36-7 | Etodolac | Under development | |
Ethyl 7-chloro-2,2-dimethylheptanoate | 2570179-39-2 | Bempedoic Acid | Under development | |
Diethyl 2,2,14,14-tetramethyl-8-oxopentadecanedioate | 738606-43-4 | Bempedoic Acid | Under development | |
2,2,14,14-tetramethyl-8-oxopentadecanedioic acid | 413624-71-2 | Bempedoic Acid | Under development | |
2-methyl-4-(2-methyl-benzoylamino)-benzoic acid | 317374-08-6 | Tolvaptan | Under development | |
7-Chloro-1,2,3,4-tetrahydro-5H-1-benzazepin-5-one | 160129-45-3 | Tolvaptan | Under development |
*Developed products would be commercially available by Q1 2024
**These products are not available for sale in countries where the patents are applicable or still valid